AstraZeneca's Type-2 Diabetes Drug Qtrilmet Approved in the EU
15 Novembre 2019 - 8:41AM
Dow Jones News
By Adriano Marchese
AstraZeneca PLC (AZN.LN) said Friday that its Qtrilmet drug has
been approved in the European Union to treat type-2 diabetes.
The drug maker said that Qtrilmet, a modified-release tablet to
improve glycaemic control in adults with type-2 diabetes, was
approved by the European Commission, based on data from five Phase
3 trials.
The drug was approved in the U.S. in May under the name Qternmet
XR.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 15, 2019 02:26 ET (07:26 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024